IPHA welcomes govt 30 million euros medicines budget

The Irish Pharmaceutical Healthcare Association (IPHA), the representative body for the research-based biopharmaceutical industry in Ireland, welcomes the allocation of 30 million euros ($34.7 million) for new, life-enhancing medicines in Budget 2026.

This level of funding is part of 217 million euros allocated to Primary Care Reimbursement System (PCRS) medicines, which supports the availability to tens of thousands of current and new patients of over 100 innovative medicines approved in the last four years, across all the major therapy areas and for rare diseases.

IPHA member companies expect to make applications for reimbursement for 32 medicines in 2026 and this funding should be used to enable faster access to these therapeutic advances for as many as 6,000 patients. These medicines would improve the standard of care for patients suffering from a number of diseases such as cancer – breast cancer, lung cancer, gynecological cancer, multiple myeloma, acute myeloid leukemia and others –ulcerative colitis, Crohn’s disease, women’s health conditions, type 2 diabetes, weight management, cardiovascular disease and Friedreich’s ataxia.